In particular, various reports have shown that emodin decreases HCC growth through the suppression of oncogenic growth signaling, such as the MAPK, PI3K-AKT, and STAT3 pathways, in both in vitro and in vivo models [9,28,29]. Here, STAT3 is linked to hepatocellular carcinoma.